Published in Mol Cell on November 25, 2009
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature (2011) 5.49
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal (2012) 1.95
Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer (2010) 1.74
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell (2012) 1.65
Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood (2015) 1.50
Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors (2010) 1.46
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer (2010) 1.43
A positive role of cadherin in Wnt/β-catenin signalling during epithelial-mesenchymal transition. PLoS One (2011) 1.40
Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin J Cancer (2011) 1.39
Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes Cancer (2013) 1.28
VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. Neuro Oncol (2012) 1.24
Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6. Mol Cell Biol (2010) 1.19
Mechanisms regulating glioma invasion. Cancer Lett (2015) 1.19
Differentiation of the brain vasculature: the answer came blowing by the Wnt. J Angiogenes Res (2010) 1.16
Beta-catenin phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphorylated in the GSK3 domain: implications for signaling. PLoS One (2010) 1.14
ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J Neurosci (2010) 1.12
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene (2013) 1.03
IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLoS One (2011) 1.02
β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells. Chemother Res Pract (2012) 0.99
Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. J Clin Invest (2014) 0.98
Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget (2014) 0.96
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization. ACS Med Chem Lett (2012) 0.93
α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes. Genes Dev (2013) 0.93
Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover. J Biol Chem (2011) 0.92
Regulation of adherens junction dynamics by phosphorylation switches. J Signal Transduct (2012) 0.92
Phosphopeptide characterization by mass spectrometry using reversed-phase supports for solid-phase β-elimination/Michael addition. J Biomol Tech (2012) 0.92
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One (2013) 0.91
The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest (2015) 0.91
ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro. Neuro Oncol (2013) 0.91
CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One (2013) 0.89
Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. Mol Cell (2017) 0.89
Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol (2014) 0.88
AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep (2012) 0.88
UVB radiation-induced β-catenin signaling is enhanced by COX-2 expression in keratinocytes. Mol Carcinog (2011) 0.87
Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin. J Gene Med (2013) 0.86
Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem (2010) 0.86
Acute alcohol exposure impairs fracture healing and deregulates β-catenin signaling in the fracture callus. Alcohol Clin Exp Res (2012) 0.86
PIPKIγ regulates β-catenin transcriptional activity downstream of growth factor receptor signaling. Cancer Res (2011) 0.85
CK2α is essential for embryonic morphogenesis. Mol Cell Biochem (2011) 0.85
ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells. Biochem Pharmacol (2011) 0.85
EGFR phosphorylates FAM129B to promote Ras activation. Proc Natl Acad Sci U S A (2015) 0.85
WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest (2015) 0.84
Epidermal growth factor receptor (EGFR) signaling regulates epiphyseal cartilage development through β-catenin-dependent and -independent pathways. J Biol Chem (2013) 0.84
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling. Oncotarget (2014) 0.84
Differential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1. J Biol Chem (2015) 0.84
Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One (2013) 0.84
Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy. Neuro Oncol (2014) 0.83
Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS One (2012) 0.82
Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One (2014) 0.82
Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway. Oncogene (2014) 0.82
Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma. Oncogene (2013) 0.82
ARF6-regulated endocytosis of growth factor receptors links cadherin-based adhesion to canonical Wnt signaling in epithelia. Mol Cell Biol (2013) 0.81
A novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathy. Cell Death Dis (2015) 0.81
Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics (2014) 0.80
CK2-NCoR signaling cascade promotes prostate tumorigenesis. Oncotarget (2013) 0.79
α-Catenin phosphorylation promotes intercellular adhesion through a dual-kinase mechanism. J Cell Sci (2015) 0.79
Chemokines induce axon outgrowth downstream of Hepatocyte Growth Factor and TCF/β-catenin signaling. Front Cell Neurosci (2013) 0.79
CK2-An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals (Basel) (2017) 0.78
Identification of dynamic changes in proteins associated with the cellular cytoskeleton after exposure to okadaic acid. Mar Drugs (2013) 0.78
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine (2016) 0.78
The role of protein kinase CK2 in glioblastoma development. Clin Cancer Res (2013) 0.78
Regulation of Endothelial Adherens Junctions by Tyrosine Phosphorylation. Mediators Inflamm (2015) 0.78
Protein kinase CK2 phosphorylates and activates p21-activated kinase 1. Mol Biol Cell (2013) 0.78
c-Cbl mediates the degradation of tumorigenic nuclear β-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget (2016) 0.77
Expression/activation of α5β1 integrin is linked to the β-catenin signaling pathway to drive migration in glioma cells. Oncotarget (2016) 0.77
FAM129B activates Ras and promotes aerobic glycolysis. Cell Cycle (2016) 0.77
Hypoxia-inducible factor-1α and Wnt/β-catenin signaling pathways promote the invasion of hypoxic gastric cancer cells. Mol Med Rep (2015) 0.77
Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion. Cell Cycle (2015) 0.77
Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech (2015) 0.77
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell (2016) 0.77
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. Int J Mol Sci (2017) 0.76
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release (2016) 0.76
Casein kinase 2 sends extracellular signal-regulated kinase nuclear. Mol Cell Biol (2011) 0.76
Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. Cell Res (2016) 0.75
Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol (2016) 0.75
Annexin-1 Mediates Microglial Activation and Migration via the CK2 Pathway during Oxygen-Glucose Deprivation/Reperfusion. Int J Mol Sci (2016) 0.75
Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer. PLoS One (2017) 0.75
Role of Matrix Metalloproteinases 2 in Spinal Cord Injury-Induced Neuropathic Pain. Ann Neurosci (2016) 0.75
MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo. Oncotarget (2016) 0.75
Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts. Drug Des Devel Ther (2015) 0.75
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. J Biol Chem (2016) 0.75
Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. Oncotarget (2017) 0.75
Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells. J Mol Genet Med (2013) 0.75
Enhancement of β-catenin activity by BIG1 plus BIG2 via Arf activation and cAMP signals. Proc Natl Acad Sci U S A (2016) 0.75
[Plasticity of WNT signaling activity in colorectal cancer]. Pathologe (2012) 0.75
More precise prediction in Chinese patients with penile squamous cell carcinoma: protein kinase CK2α catalytic subunit (CK2α) as a poor prognosticator. Oncotarget (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Cell migration: integrating signals from front to back. Science (2003) 29.13
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Cell migration: a physically integrated molecular process. Cell (1996) 23.49
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Wnt signaling and cancer. Genes Dev (2000) 18.53
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol (1998) 9.24
Deconstructing the cadherin-catenin-actin complex. Cell (2005) 8.39
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell (2005) 7.62
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science (2000) 7.25
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
One-thousand-and-one substrates of protein kinase CK2? FASEB J (2003) 6.89
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol (1994) 6.00
Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci U S A (1995) 5.54
A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol (2000) 5.46
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J (2003) 5.11
Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell (2001) 5.01
MAP kinases. Chem Rev (2001) 4.70
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol (1994) 4.34
Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol (1990) 4.05
Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol (2008) 3.87
Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell (2003) 3.87
The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol (1997) 3.52
Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol (2005) 3.20
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol (2005) 3.09
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res (1995) 3.04
Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol (2004) 2.79
Catenins: keeping cells from getting their signals crossed. Dev Cell (2006) 2.70
Structure of the dimerization and beta-catenin-binding region of alpha-catenin. Mol Cell (2000) 2.61
Functional domains of alpha-catenin required for the strong state of cadherin-based cell adhesion. J Cell Biol (1999) 2.59
p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol (2003) 2.58
Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J (2001) 2.50
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol (1999) 2.30
Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene (2001) 2.25
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol (2001) 2.24
ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life (2006) 2.24
IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene (2001) 2.03
Molecular architecture of adherens junctions. Curr Opin Cell Biol (2001) 1.94
Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev (2005) 1.94
Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. J Biol Chem (2000) 1.90
Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol (2007) 1.76
Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J (2002) 1.60
Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Exp Cell Res (2002) 1.55
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem (2003) 1.51
Stimulation of casein kinase II by epidermal growth factor: relationship between the physiological activity of the kinase and the phosphorylation state of its beta subunit. Proc Natl Acad Sci U S A (1990) 1.49
Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle (2004) 1.47
Protein kinase CKII regulates the interaction of beta-catenin with alpha-catenin and its protein stability. J Cell Sci (2002) 1.44
Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci U S A (1990) 1.37
The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res (1999) 1.34
CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol (2006) 1.30
CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem (2005) 1.30
alpha-catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin*T-cell factor*DNA complex. J Biol Chem (2000) 1.28
A beta-catenin/engrailed chimera selectively suppresses Wnt signaling. J Cell Sci (2000) 1.25
Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets (2004) 1.21
Regulation of casein kinase II by growth factors: a reevaluation. Cell Mol Biol Res (1994) 1.11
Regulation of beta-catenin signaling and maintenance of chondrocyte differentiation by ubiquitin-independent proteasomal degradation of alpha-catenin. J Biol Chem (2005) 1.10
Counting on mitogen-activated protein kinases--ERKs 3, 4, 5, 6, 7 and 8. Cell Signal (2004) 1.09
Protein kinase CK2: a new view of an old molecular complex. EMBO Rep (2004) 1.03
Interactions between protein kinase CK2 and Pin1. Evidence for phosphorylation-dependent interactions. J Biol Chem (2002) 1.01
CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation. Oncogene (2002) 0.99
Distinct activities of the alpha-catenin family, alpha-catulin and alpha-catenin, on beta-catenin-mediated signaling. Mol Cell Biol (2004) 0.98
The disruption of adherens junctions is associated with a decrease of E-cadherin phosphorylation by protein kinase CK2. Exp Cell Res (2000) 0.96
Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182. Biochem J (2001) 0.94
Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Neurosurg Rev (2000) 0.90
Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc (2002) 0.89
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature (2011) 5.49
A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature (2005) 5.13
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science (2006) 4.42
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol (2004) 3.70
Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature (2007) 3.57
Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell (2003) 3.42
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res (2007) 2.66
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Retracted Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med (2010) 2.43
Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell (2008) 2.29
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol (2012) 2.15
Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther (2006) 2.13
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta (2007) 2.07
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res (2010) 2.05
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol (2014) 2.04
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol (2011) 1.91
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86
Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res (2011) 1.84
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol (2006) 1.83
RNAa is conserved in mammalian cells. PLoS One (2010) 1.81
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem (2001) 1.70
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 1.67
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell (2002) 1.67
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell (2012) 1.65
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res (2002) 1.61
Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther (2005) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PLoS One (2012) 1.59
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A (2013) 1.57
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res (2006) 1.52
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res (2012) 1.52
Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther (2004) 1.49
FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell (2009) 1.47
Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene (2005) 1.45
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev (2005) 1.44
Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med (2008) 1.44
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem Cell Biol (2004) 1.41
c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell (2007) 1.40
Polymorphisms of DNA repair genes and risk of glioma. Cancer Res (2004) 1.39
Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling. Angew Chem Int Ed Engl (2010) 1.37
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem (2002) 1.35
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res (2005) 1.35
The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med (2005) 1.33
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood (2011) 1.32
Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res (2009) 1.31
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene (2005) 1.29
Activation of MTK1/MEKK4 by GADD45 through induced N-C dissociation and dimerization-mediated trans autophosphorylation of the MTK1 kinase domain. Mol Cell Biol (2007) 1.29
Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett (2013) 1.28
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol (2015) 1.27
Real-time video imaging of protease expression in vivo. Theranostics (2011) 1.27
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy (2008) 1.27
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J Biol Chem (2008) 1.27
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest (2011) 1.27
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res (2011) 1.24
Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene (2003) 1.24
Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J Biol Chem (2003) 1.24
PKM2 functions as a histone kinase. Cell Cycle (2012) 1.24
Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res (2004) 1.22
The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci (2005) 1.21
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene (2002) 1.20
Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest (2011) 1.20
ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol (2005) 1.19
The shape of things to come: an emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal (2005) 1.19